This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutEfficacySafetyDosingSupport & ResourcesPatient SupportMaterialsVideos

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.

Once-weekly administration1A multidose, disposable pen that is prefilled and ready to use, with no reconstitution required1

See below for an overview of NGENLA dosing and administration steps.

  • Once-weekly dosing is based on weight—0.66 mg/kg of body weight administered once weekly by subcutaneous injection 
  • No dose recommendations can be made for patients over the age of 65 years, or patients with renal impairment or hepatic impairment, as NGENLA has not been studied in these patients
  • The safety and efficacy of NGENLA in neonates, infants and children less than 3 years of age have not yet been established. No data is available 

Refer to full Patient Information Leaflet for detailed steps.

  • Patients should administer NGENLA once weekly, on the same day each week, at any time of the day
  • The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days (>72 hours)
  • NGENLA can be given in the abdomen, thighs, buttocks, or upper arms. The site of injection should be rotated at each administration
  • If more than one injection is required to deliver a complete dose, each injection should be administered at a different injection site

Getting ready

  • Wash and dry your hands
  • Use the pen straight from the refrigerator or leave it at room temperature for up to 30 minutes for a more comfortable injection

Choose and clean your injection site

  • Injection should be given in the abdomen (belly), thighs, buttocks, or upper arms
  • Select a different site for each injection
  • Do not inject into bony areas, areas that are bruised, red, sore, or have scars or skin conditions
  • Clean the injection site with an alcohol swab and let dry. Do not touch injection site after cleaning

Prepare your injection

  • Pull off the pen cap and set it aside for after the injection. Check that the medicine is colorless to slightly light yellow and is free of flakes or particles
  • Take a new needle and pull off its protective paper. Attach a new needle for each injection
  • Pull off the outer needle cover. Set it aside for later to help remove the needle
  • Pull off the inner needle cap. Throw away inner needle cap in a sharps container

Set your prescribed dose

  • Turn the knob to set your dose; dose knob turns 0.5 mg at a time for the NGENLA 60-mg pen and 0.2 mg at a time for the NGENLA 24-mg pen
  • Check the dose window to make sure you have set the correct dose
  • If your dose is more than 30 mg when using the NGENLA 60-mg pen, or more than 12 mg when using the NGENLA 24-mg pen, you will need more than 1 injection. Use a new needle for each injection

Inject your dose

  • Hold the pen so you can see the numbers in the dose window
  • Insert the needle straight into your skin
  • Press the injection button until it can’t go down any further and “0” is displayed in the dose window. Hold the button down for 10 seconds, then let go of the injection button and remove the pen from the injection site by pulling the needle straight out

Finish up

  • Carefully replace the outer needle cover
  • Unscrew the capped needle and dispose of it in a sharps container
  • Do not reuse needles
  • Replace the pen cap. If there is any medicine left, store it in the refrigerator between uses

If setting up the first use of new pen:

  • Turn the dose knob to 1.0 for the 60-mg pen; for the 24-mg pen, set dose knob to 0.4
  • Hold the pen with the needle pointing up. Tap cartridge holder gently to float any air bubbles to the top
  • Press the injection button until it cannot go any further and you see “0” in the dose window. If liquid appears at needle tip, the pen is set up. If liquid has not appeared, repeat first-use steps
How to use NGENLA

Step-by-step video tutorial on how to prepare and give an injection with the NGENLA prefilled pen. You can also download the complete Instructions for Use here.

Refer to full Patient Information Leaflet (PIL) for detailed steps. NGENLA 24mg pen and NGENLA 60mg pen PILs are available to download from

Consider NGENLA for all your appropriate patients from age 3 years with paediatric growth hormone deficiency1

Ngenla▼ Prescribing Information

References:NGENLA® Summary of Product Characteristics.Ngenla 24mg Pen Patient Information LeafletNgenla 60mg Pen Patient Information Leaflet

Access data on the efficacy of NGENLA.

View efficacy data

Learn more about clinical safety data of NGENLA in children with GH deficiency.

View safety data

Support for your patients throughout their treatment journey.

Explore more

Legal Category: S1A
Further information is available upon request

PP-NGE-IRL-0018  Date of Preparation Dec 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.